

TOP 10 Drug Discovery Technologies – Strategic Analysis and Global Forecasts

<https://marketpublishers.com/r/T3013CBF7A8EN.html>

Date: November 2010

Pages: 311

Price: US\$ 5,650.00 (Single User License)

ID: T3013CBF7A8EN

Abstracts

Top 10 drug discovery technologies – strategic analysis and global forecasts (2010 to 2015)

The top 10 drug discovery technologies play a vital role in the growth of the entire pharmaceutical industry as they are the key contributors in the swift introduction of blockbusters and innovative drugs, which is the most important aspect for the pharmaceutical companies. The applications of these technologies in the introduction of drugs for diverse diseases such as cancer, CVD, CNS disorders such as Parkinson's and Alzheimer's and other serious chronic diseases have created significant opportunities for the market growth in the future. The slow growth of the introduction of new blockbuster drugs is a major concern which the drug development companies are catering to by using these top technologies.

The global top 10 drug discovery technologies market is expected to be around \$ 30.8 billion in 2010 and estimated to reach \$ 54 billion mark in 2015, growing at a CAGR of 11.9 % from 2010-2015. The market for high throughput screening accounts for the largest share with approximately 33% of the entire market for top 10 drug discovery technologies. This huge market share is mainly due to the increasing applications of cell based assays and robotics in the parallel screening of compounds.

Scope of the report

This research report includes following drug discovery technologies:

High throughput screening (robotics and automation, cell based assays,

miniaturization, high content screening and ultra high throughput screening)

Bioanalytical instruments (mass spectrometry, NMR, micro plate readers and chemotherapy instruments)

Pharmacogenomics

Combinatorial chemistry

Genomics (functional and structural genomics)

Biochips (DNA microarrays, lab on a chip, proteomics microarrays)

Bioinformatics

Proteomics (2DGE, two hybrid systems, isotope encoding and activity based assays)

RNAi (siRNA, miRNA, ddRNAi, short hairpin RNAs)

Nanotechnology (Atomic force microscopy, nano mass spectroscopy, dip pen nanolithography and other nanotechnologies)

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for covering the sub-segments and micro-markets. In addition, the report also provides more than 20 company profiles covering all the sub-segments.

What makes our reports unique?

We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.

We provide 10% customization. Normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and

we get a loyal customer.

We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.

Comprehensive market analysis for the following sectors:

Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered

Which are the high-growth segments/cash cows and how is the market segmented in terms of applications and materials?

What are market estimates and forecasts; which markets are doing well and which are not?

Where are the gaps and opportunities; what is driving the market?

Which are the key playing fields? Which are the winning edge imperatives?

How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts working with MarketsandMarkets come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients

grow by providing qualitative business insights with our huge market intelligence repository.

Contents

EXECUTIVE SUMMARY

Objective

Market scenario

1 INTRODUCTION

1.1 Key take-aways

1.2 Report description

1.3 Markets covered

1.4 Research methodology

1.5 Stakeholders

2 SUMMARY

3 MARKET OVERVIEW

3.1 Market segmentation

3.2 High throughput screening & bioanalytical instruments leading the market

3.3 Patent analysis

4 DRIVING FACTOR ANALYSIS

4.1 Drivers

4.1.1 Contract research boosting technology adoption

4.1.2 Collaborations between academia & pharmaceutical industry

4.1.3 Increased necessity for ADME/toxicity technologies

4.2 Opportunities

4.2.1 Offshoring scenario for drug discovery

5 HIGH THROUGHPUT SCREENING

5.1 Introduction

5.2 Market overview

5.3 Burning issues & winning imperatives

5.3.1 Increasing participation from academic research

5.3.2 High throughput screening set up: pharmaceutical vs academic

5.4 Ultra high throughput screening

5.5 Robotics & automation

5.6 Miniaturization

5.7 High content screening

5.7.1 Opportunities

5.7.1.1 GPCR drug discovery

5.8 Cell based assays

6 BIOANALYTICAL INSTRUMENTS

6.1 Introduction

6.2 Burning issues & trends

6.2.1 Pharmaceutical industry a major end client

6.2.2 Agilent penetration in bioanalytical instruments market

6.2.3 Outsourcing scenario

6.3 Mass spectrometry

6.3.1 Upcoming technology - MalDI-QMS

6.4 Microplate readers

6.5 Nuclear magnetic resonance

6.6 Chemotherapy instruments

7 PHARMACOGENOMICS

7.1 Introduction

7.2 Pharmacogenomics applications in drug development

7.3 Burning issues

7.3.1 Commercial hurdles in drug development

7.3.1.1 Cost issues in clinical development

7.3.1.2 FDA approval

7.3.1.3 Ethical issues

7.3.2 Pharmacogenomics for drug reintroduction

7.3.3 Pharmacogenomics applications in existing drugs

7.4 Key trends in the pharmacogenomics technology market

7.4.1 Regulatory initiatives boosting adoption for pharmacogenomics technology

7.4.2 Rise in pharmacogenomics consortia boost technology based research

7.4.3 Increasing importance of databases

7.5 Future prospects for pharmacogenomics technology research

7.6 Pharmacogenomics products: pricing effects

7.6.1 Case study: high priced herceptin

- 7.6.2 Pharmacogenomics cost effectiveness
- 7.7 Pharmacogenomics technology: short & long term benefits
 - 7.7.1 Improvement in patient safety
 - 7.7.2 Increase in drug effectiveness
 - 7.7.3 Selection of medication for chronic diseases
 - 7.7.4 Better economic efficiency for the healthcare system
 - 7.7.5 Improved patient access to drugs

8 COMBINATORIAL CHEMISTRY

- 8.1 Introduction
- 8.2 Market drivers
 - 8.2.1 Technological advances boost adoption of combinatorial chemistry
 - 8.2.2 Process enhancement results in better compounds
 - 8.2.3 Collaborative approach
 - 8.2.4 Need for novel compounds acts as market opportunity
- 8.3 Stakeholders characteristics
- 8.4 Burning issues
- 8.5 Key trends and market boosters
 - 8.5.1 Increased recognition of combinatorial chemistry technology
 - 8.5.2 Faster drug discovery

9 GENOMICS

- 9.1 Introduction
- 9.2 Winning imperatives
 - 9.2.1 Reducing cost for whole genome sequencing
- 9.3 Functional genomics
- 9.4 Structural genomics

10 BIOCHIPS

- 10.1 Introduction
- 10.2 Burning issues
 - 10.2.1 Business trends
 - 10.2.2 Patent disputes
 - 10.2.3 Competition
- 10.3 Industry trends
 - 10.3.1 Next generation technology: microfluidics with CD-ROM

- 10.3.2 Biochips in biomarker development
- 10.3.3 Outsourcing the biochip technology
- 10.4 DNA microarrays
 - 10.4.1 Market drivers
 - 10.4.1.1 Increased utilization in complex diseases
 - 10.4.1.2 Sequence data proliferation
 - 10.4.1.3 Easy-access programs
- 10.5 Lab on a chip
 - 10.5.1. New technology & cost saving by lab on a chip boost the market
- 10.6 Proteomics microarrays
 - 10.6.1 Burning issues and trends
 - 10.6.1.1 Technical lags
 - 10.6.1.2 Human protein microarray for multiple protein analysis

11 BIOINFORMATICS

- 11.1 Introduction
- 11.2 Burning issues and trends
 - 11.2.1 Outsourcing
 - 11.2.2 Allocation of grants

12 PROTEOMICS

- 12.1 Introduction
- 12.2 Industry trends
 - 12.2.1 Funding for proteomics research
 - 12.2.2 Proteomics in anti cancer drug discovery
- 12.3 Two dimensional gel electrophoresis- 2DGE
- 12.4 Two-hybrid systems

13 RNAI

- 13.1 Technology overview
- 13.2 Winning imperatives
 - 13.2.1 Core competency acquisition
- 13.3 Opportunity in RNAi drug discovery
 - 13.3.1 RNAi based cholesterol drugs
 - 13.3.2 Cancer drugs
- 13.4 SiRNA

13.5 MiRNAS

13.6 Other RNAi technologies

14 NANOTECHNOLOGY

14.1 Introduction

14.2 Healthcare application areas for nanotechnology

14.2.1 Biomedical research

14.2.2 Therapeutics

14.2.3 Diagnostics

14.3 Burning issues and trends

14.3.1 Regulatory & health issues

14.3.2 Increase in funding

14.4 Atomic force microscopy (AFM)

14.5 Nano-mass spectroscopy

14.6 Dip-pen Nanolithography

15 GEOGRAPHICAL ANALYSIS

15.1 Introduction

15.2 North America

15.3 Europe

15.4 Asia

15.5 ROW

16 COMPETITIVE LANDSCAPE

16.1 Market share for drug discovery technologies

16.2 Agreements & collaborations

16.3 New product launch

16.4 End clients for top 10 drug discovery technologies

17 COMPANY PROFILES

17.1 ABBOTT LABORATORIES INC.

17.1.1 Overview

17.1.2 Primary business

17.1.3 Strategy

17.1.4 Developments

17.2 AFFYMETRIX INC.

- 17.2.1 Overview
- 17.2.2 Primary business
- 17.2.3 Strategy
- 17.2.4 Developments

17.3 AGILENT TECHNOLOGIES INC.

- 17.3.1 Overview
- 17.3.2 Primary business
- 17.3.3 Strategy
- 17.3.4 Developments

17.4 ALBANY MOLECULAR RESEARCH INC.

- 17.4.1 Overview
- 17.4.2 Primary business
- 17.4.3 Strategy
- 17.4.4 Developments

17.5 ARQULE INC.

- 17.5.1 Overview
- 17.5.2 Primary business
- 17.5.3 Strategy
- 17.5.4 Developments

17.6 ASTRAZENECA PLC.

- 17.6.1 Overview
- 17.6.2 Primary business
- 17.6.3 Strategy
- 17.6.4 Developments

17.7 BIO-RAD LABORATORIES INC.

- 17.7.1 Overview
- 17.7.2 Primary business
- 17.7.3 Strategy
- 17.7.4 Developments

17.8 CALIPER LIFE SCIENCES INC.

- 17.8.1 Overview
- 17.8.2 Primary business
- 17.8.3 Strategy
- 17.8.4 Developments

17.9 CELERA CORP

- 17.9.1 Overview
- 17.9.2 Primary business
- 17.9.3 Strategy

- 17.9.4 Developments
- 17.10 CHARLES RIVER LABORATORIES INTERNATIONAL INC.
 - 17.10.1 Overview
 - 17.10.2 Primary business
 - 17.10.3 Strategy
 - 17.10.4 Developments
- 17.11 CHEMBRIDGE CORP
 - 17.11.1 Overview
 - 17.11.2 Primary business
 - 17.11.3 Strategy
 - 17.11.4 Developments
- 17.12 EVOTEC AG
 - 17.12.1 Overview
 - 17.12.2 Primary business
 - 17.12.3 Strategy
 - 17.12.4 Developments
- 17.13 F. HOFFMANN-LA ROCHE LTD.
 - 17.13.1 Overview
 - 17.13.2 Primary business
 - 17.13.3 Strategy
 - 17.13.4 Developments
- 17.14 GYROS AB
 - 17.14.1 Overview
 - 17.14.2 Primary business
 - 17.14.3 Strategy
 - 17.14.4 Developments
- 17.15 INCYTE CORP
 - 17.15.1 Overview
 - 17.15.2 Primary business
 - 17.15.3 Strategy
 - 17.15.4 Developments
- 17.16 LIFE TECHNOLOGIES CORP
 - 17.16.1 Overview
 - 17.16.2 Primary business
 - 17.16.3 Strategy
 - 17.16.4 Developments
- 17.17 SHIMADZU CORP
 - 17.17.1 Overview
 - 17.17.2 Primary business

- 17.17.3 Strategy
- 17.17.4 Developments
- 17.18 PERKINELMER INC.
 - 17.18.1 Overview
 - 17.18.2 Primary business
 - 17.18.3 Strategy
 - 17.18.4 Developments
- 17.19 SIGMA-ALDRICH CORP
 - 17.19.1 Overview
 - 17.19.2 Primary business
 - 17.19.3 Strategy
 - 17.19.4 Developments
- 17.20 TECAN GROUP LTD.
 - 17.20.1 Overview
 - 17.20.2 Primary business
 - 17.20.3 Strategy
 - 17.20.4 Developments
- 17.21 THERMO FISHER SCIENTIFIC INC.
 - 17.21.1 Overview
 - 17.21.2 Primary business
 - 17.21.3 Strategy
 - 17.21.4 Developments

APPENDIX

- U.S. patents
- EUROPE patents
- JAPAN patents

List Of Tables

LIST OF TABLES

- 1 Global top 10 drug discovery technologies market 2008 – 2015 (\$Million)
- 2 Estimated time saving by CRO in clinical trials
- 3 Global high throughput screening market, by products 2008 – 2015 (\$Million)
- 4 High throughput screening market, by geography 2008 – 2015 (\$Million)
- 5 HTS infrastructural/resource comparison for pharmaceutical and academic centers
- 6 Ultra high throughput screening market, by geography 2008 – 2015 (\$Million)
- 7 Robotics and automation market, by geography 2008 – 2015 (\$Million)
- 8 Miniaturization market, by geography 2008 – 2015 (\$Million)
- 9 High content screening market, by geography 2008 – 2015 (\$Million)
- 10 Cell based assays market, by geography 2008 – 2015 (\$Million)
- 11 Global bioanalytical instruments market, by products 2008 – 2015 (\$Million)
- 12 Bioanalytical instruments market, by geography 2008 – 2015 (\$Million)
- 13 Global mass spectrometry market, by products 2008 – 2015 (\$Million)
- 14 Mass spectrometry market, by geography 2008 – 2015 (\$Million)
- 15 Microplate Readers Market, By Geography 2008 – 2015 (\$Million)
- 16 NMR market, by geography 2008 – 2015 (\$Million)
- 17 Chemotherapy instruments market, by geography 2008 – 2015 (\$Million)
- 18 Pharmacogenomics market, by geography 2008 – 2015 (\$Million)
- 19 Combinatorial chemistry market, by geography 2008 – 2015 (\$Million)
- 20 Cost comparison between traditional and combinatorial chemistry
- 21 Global genomics market, by products 2008 – 2015 (\$Million)
- 22 Genomics market, by geography 2008 – 2015 (\$Million)
- 23 Functional genomics market, by geography 2008 – 2015 (\$Million)
- 24 Structural genomics market, by geography 2008 – 2015 (\$Million)
- 25 Global biochips market, by segment 2008 – 2015 (\$Million)
- 26 Biochips market, by geography 2008 – 2015 (\$Million)
- 27 Patent disputes within the biochips market
- 28 DNA microarrays market, by geography 2008 – 2015 (\$Million)
- 29 Lab on a chip market, by geography 2008 – 2015 (\$Million)
- 30 Proteomics microarrays market, by geography 2008 – 2015 (\$Million)
- 31 Global bioinformatics market, by products 2008 – 2015 (\$Million)
- 32 Bioinformatics market, by geography 2008 – 2015 (\$Million)
- 33 Global proteomics market, by products 2008 – 2015 (\$Million)
- 34 Proteomics market, by geography 2008 – 2015 (\$Million)
- 35 2DGE market, by geography 2008 – 2015 (\$Million)

- 36 Two hybrid systems market, by geography 2008 – 2015 (\$Million)
- 37 Global RNAi market, by products 2008 – 2015 (\$Million)
- 38 RNAi market, by geography 2008 – 2015 (\$Million)
- 39 SiRNA market, by geography 2008 – 2015 (\$Million)
- 40 MiRNA market, by geography 2008 – 2015 (\$Million)
- 41 Global other RNAi technologies market, by products 2008 – 2015 (\$Million)
- 42 Other RNAi technologies market, by geography 2008 – 2015 (\$Million)
- 43 Global nanotechnology market, by products 2008 – 2015 (\$Million)
- 44 Nanotechnology market, by geography 2008 – 2015 (\$Million)
- 45 Comparison of AFM technology with other microscopy technology
- 46 Atomic force microscopy market, by geography 2008 – 2015 (\$Million)
- 47 Nano-mass spectroscopy market, by geography 2008 – 2015 (\$Million)
- 48 Dip-pen Nanolithography market, by geography 2008 – 2015 (\$Million)
- 49 North American top 10 drug discovery technologies market 2008 – 2015 (\$Million)
- 50 European top 10 drug discovery technologies market 2008 – 2015 (\$Million)
- 51 Asian top 10 drug discovery technologies market 2008 – 2015 (\$Million)
- 52 RoW top 10 drug discovery technologies market 2008 – 2015 (\$Million)
- 53 Agreements and collaborations (2009 – 2010)
- 54 New product development (2009 – 2010)

List Of Figures

LIST OF FIGURES

- 1 Revenue analysis for top 10 drug discovery technologies
- 2 Top 10 drug discovery technologies market segmentation
- 3 Relative market scenario (2010)
- 4 Patent analysis by geography
- 5 Patent analysis by competitors 2005 – 2010
- 6 High throughput screening in drug discovery
- 7 Approximate industrial demand for bioanalytical instruments (2010)
- 8 Cost saving in comparison with high throughput screening
- 9 Approximate end client share for microplate readers
- 10 Drug development process and pharmacogenomics applications
- 11 Future advancements in the pharmacogenomics research
- 12 Cost associated with pharmacogenomics based tests
- 13 Long term goals/benefits for pharmacogenomics
- 14 Dollar value offered, by technology providers
- 15 Time and cost saving by implementation of combinatorial chemistry
- 16 Reducing costs for whole genome sequencing
- 17 Major end clients for biochip technology market
- 18 Historical data for DNA microarray based collaborations
- 19 Applications of lab-on-a-chip technology in drug discovery
- 20 MiRNA research efforts
- 21 Applications areas of MiRNA
- 22 MiRNA in drug discovery
- 23 Nanotechnology applications
- 24 Global market for top 10 drug discovery technologies
- 25 Approximate market share for overall drug discovery technologies
- 26 Approximate end client share for top 10 drug discovery technologies

I would like to order

Product name: TOP 10 Drug Discovery Technologies – Strategic Analysis and Global Forecasts

Product link: <https://marketpublishers.com/r/T3013CBF7A8EN.html>

Price: US\$ 5,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T3013CBF7A8EN.html>